Shinobi Therapeutics: Funding, Investors & Team (Oct 2026)
Shinobi Therapeutics specializes in developing hypoimmune CD8αβ iPS-T cells that collaborate with the immune system to address cancer and other illnesses. By using cutting-edge immune evasion techniques, the company seeks to enhance the efficiency and availability of cell therapies. Shinobi's unique strategy is designed to lower expenses and enhance patient results by providing long-lasting responses and the ability to administer additional doses.
Shinobi Therapeutics has raised $119M across 2 funding rounds on record, the most recent a Series A of $68.0M announced in Aug 2024.
That round is above the $8.4M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Shinobi Therapeutics Company Profile and Key Stats
Latest funding round on record: Aug 2024.
Shinobi Therapeutics Funding Rounds
Shinobi Therapeutics raised $51.0M in a Series A announced in Dec 2023.
8 months later, a Series A of $68.0M was announced in Aug 2024.
Shinobi Therapeutics Founders and Leadership Team
Contact details for the Shinobi Therapeutics team: 1 of 2 have an email address on file.
Start 14-day free trial →Shinobi Therapeutics Funding Compared to Other Biotechnology Startups
Shinobi Therapeutics' latest round of $68.0M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Shinobi Therapeutics in Biotechnology and South San Francisco
Companies Similar to Shinobi Therapeutics
Prolific Machines is a biotech company located in San Francisco, California, that was established in 2020. It…
Altay Therapeutics is a biotech company focused on finding and discovering small molecule therapies for…
Kallyope, we believe that the gut is the gateway to our internal world. Containing millions of neurons, the…
Astrocyte Pharmaceuticals is a drug development company that helps in the recovery and well-being of brain…
Tiny Health offers a gut health test specifically designed for mothers and babies aged 0 to 3 years.…
Junevity is dedicated to using cutting-edge transcription factor medicines to combat age-related diseases.…
Arkea Bio creates technology aimed at reducing greenhouse gas (GHG) emissions in the agricultural sector.
Serán is a contract development and manufacturing organization providing a comprehensive suite of…
Precision’s goal is to provide breakthrough treatments for the one billion patients worldwide suffering from…
Enveda is a biotechnology company that utilizes AI-powered tools to explore and characterize molecules from…
Avery Therapeutics, Inc. is a company dedicated to developing tissue engineered therapeutics to treat…
Shinobi Therapeutics Funding FAQs
What does Shinobi Therapeutics do?
Shinobi Therapeutics specializes in developing hypoimmune CD8αβ iPS-T cells that collaborate with the immune system to address cancer and other illnesses. By using cutting-edge immune evasion techniques, the company seeks to enhance the efficiency and availability of cell therapies. Shinobi's unique strategy is designed to lower expenses and enhance patient results by providing long-lasting responses and the ability to administer additional doses.
How much funding has Shinobi Therapeutics raised?
Shinobi Therapeutics has raised $119M across 2 rounds on record. The most recent is a Series A of $68.0M announced in Aug 2024.
When did Shinobi Therapeutics last raise funding?
Shinobi Therapeutics' most recent funding round on record is a Series A of $68.0M, announced in Aug 2024.
Who founded Shinobi Therapeutics?
FundedIQ lists Shin Kaneko (Founder) at Shinobi Therapeutics.
Who is the CEO of Shinobi Therapeutics?
Dan Kemp is listed as CEO at Shinobi Therapeutics.
Where is Shinobi Therapeutics headquartered?
Shinobi Therapeutics is based in South San Francisco, California, United States.
How many employees does Shinobi Therapeutics have?
Shinobi Therapeutics is in the 11-50 employee band.
How does Shinobi Therapeutics' funding compare to other Biotechnology startups?
Shinobi Therapeutics' latest round of $68.0M is above the $8.4M median round size for Biotechnology companies on FundedIQ across 4,185 tracked companies over the last two years.
About FundedIQ's Shinobi Therapeutics Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Shinobi Therapeutics is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Startup funding intelligence on every funded startup: the round, the investors and the founders, as a file in your inbox or searchable in the app.
Radar from $49/mo · Pro from $149/mo. Card required, nothing charged until day 15, and we email you 3 days before that. Need something specific? Custom plans from $499/mo.